PD-L1 in Breast Cancer: Comparative Analysis of Three Different Antibodies

The Programmed cell death-1 and its ligand-1 (PD-L1) interaction serve as a regulatory check against excessive immune response to antigen and autoimmunity. We compared the performance of three different PD-L1 antibodies (Ventana SP263, Dako 22C3 and BioCare RbMCAL10 antibodies) in 136 invasive ductal carcinoma specimens including 43 primary, 48 locally metastatic and 46 distantly metastatic disease. PD-L1 expression was correlated with clinicopathologic parameters including tumor size, grade, lymphovascular invasion, estrogen receptor (ER), progesterone receptor (PgR), HER2, Ki67, molecular type, TN status.

http://ift.tt/2g6QmNY